Eden Biodesign Selected by Omnio Healer AB for cGMP Production of Clinical Trial Product in Wound Healing and Anti-infection
8/6/2009 8:35:32 AM
LIVERPOOL, United Kingdom & RESEARCH TRIANGLE PARK, N.C., & UMEÅ, Sweden--(BUSINESS WIRE)--Eden Biodesign and Omnio Healer AB, a pioneer company that develops novel therapies for wound healing and anti-infection, today announced that they have entered into a partnership agreement. Based on a novel therapeutic concept for wound healing and anti-infection, Omnio Healer is developing drug candidates with potent pro-inflammatory functions, and under this new agreement, Eden Biodesign will provide process development and cGMP production services relating to Omnio Healer’s lead recombinant protein candidate. Indeed, the agreement with Eden Biodesign relates to the expression of proteins through mammalian cell culture for use against several clinical indications primarily focused on chronic eardrum wound studies.
comments powered by